IceCure Medical Ltd (NASDAQ:ICCM) Short Interest Down 52.3% in March

IceCure Medical Ltd (NASDAQ:ICCM) was the target of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 285,500 shares, a decrease of 52.3% from the February 28th total of 598,100 shares. Approximately 1.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 378,700 shares, the days-to-cover ratio is currently 0.8 days.

IceCure Medical Price Performance

NASDAQ:ICCM traded up $0.01 on Friday, hitting $1.11. The company had a trading volume of 221,593 shares, compared to its average volume of 521,961. IceCure Medical has a 52 week low of $0.48 and a 52 week high of $1.66. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $61.61 million, a price-to-earnings ratio of -3.83 and a beta of 0.37. The firm has a 50 day moving average of $1.32 and a two-hundred day moving average of $0.99.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The firm had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.07 million. IceCure Medical had a negative net margin of 376.85% and a negative return on equity of 124.44%. On average, research analysts anticipate that IceCure Medical will post -0.28 earnings per share for the current year.

Institutional Trading of IceCure Medical

An institutional investor recently raised its position in IceCure Medical stock. Geode Capital Management LLC lifted its stake in shares of IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,453 shares of the company’s stock after acquiring an additional 14,893 shares during the quarter. Geode Capital Management LLC owned approximately 0.07% of IceCure Medical worth $44,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 0.62% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.50 target price on shares of IceCure Medical in a research report on Friday.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.